|
|
萘环类PD-1/PD-L1抑制剂的设计、合成及生物活性评价
|
Abstract:
以BMS-1018为先导化合物，通过替换联苯片段为萘环以及生物电子等排原理，结合分子对接技术，设计并合成了两个系列共18个新型萘环类PD-1/PD-L1小分子抑制剂，结构经1H-NMR和ESI-MS谱确证。采用均相时间分辨荧光法评价目标化合物对PD-1/PD-L1结合的抑制活性。结果表明，所有目标化合物对PD-1/PD-L1均显示不同程度的抑制活性。其中6个化合物A-8、A-9和B-5、B-6、B-8、B-9的活性较为突出，值得进一步研究。
Using BMS-1018 as the lead compound, two series of novel naphthalene-based PD-1/PD-L1 small molecule inhibitors were designed and synthesized by replacing the biphenyl moiety with a naph-thalene ring and applying the principle of bioisosterism combined with molecular docking technol-ogy. The structures of the target compounds were confirmed by 1H-NMR and ESI-MS. The inhibitory activity of the compounds against the PD-1/PD-L1 interaction was evaluated by homogeneous time-resolved fluorescence. The results showed that all the target compounds displayed different degrees of inhibitory activity. Among them, six compounds A-8, A-9 and B-5, B-6, B-8, B-9 have out-standing activities, which are worthy of further study.
| [1] | Chen, L. and Flies, D.B. (2013) Molecular Mechanisms of T Cell Co-Stimulation and Co-Inhibition. Nature Reviews Immunology, 13, 227-242. https://doi.org/10.1038/nri3405 |
| [2] | Mohme, M., Riethdorf, S. and Pantel, K. (2017) Circulating and Disseminated Tumour Cells-Mechanisms of Immune Surveillance and Escape. Nature Reviews Clinical Oncology, 14, 155-167. https://doi.org/10.1038/nrclinonc.2016.144 |
| [3] | Lin, X., Lu, X., Luo, G. and Xiang, H. (2020) Progress in PD-1/PD-L1 Pathway Inhibitors: From Biomacromolecules to Small Molecules. European Journal of Medicinal Chemistry, 186, 111876-111905.
https://doi.org/10.1016/j.ejmech.2019.111876 |
| [4] | Li, X., Shao, C., Shi, Y. and Han, W. (2018) Lessons Learned from the Blockade of Immune Checkpoints in Cancer Immunotherapy. Journal of Hematology & Oncology, 11, 31-56. https://doi.org/10.1186/s13045-018-0578-4 |
| [5] | van der Zanden, S.Y., Luimstra, J.J., Neefjes, J., Borst, J. and Ovaa, H. (2020) Opportunities for Small Molecules in Cancer Immunotherapy. Trends in Immunology, 41, 493-511. https://doi.org/10.1016/j.it.2020.04.004 |
| [6] | Chupak, L.S. and Zheng, X. (2015) Compounds Useful as Immuno-modulators. WO2015034820 A1. |
| [7] | Chupak, L.S., Ding, M., Martin, S.W., Zheng, X., Hewawasam, P., Connolly, T.P., Xu, N., Yeung, K., Zhu, J. and Langley, D.R. (2015) Compounds Useful as Immunomodulators. WO2015160641 A1. |
| [8] | Skalniak, L., Zak, K.M., Guzik, K., Magiera, K., Musielak, B., Pachota, M., Szelazek, B., Kocik, J., Grudnik, P., Tomala, M., Krzanik, S., Pyrc, K., D？mling, A., Dubin, G. and Holak, T.A. (2017) Small-Molecule Inhibitors of PD-1/PD-L1 Immune Checkpoint Alleviate the PD-L1-Induced Exhaustion of T-Cells. Oncotarget, 8, 72167-72181.
https://doi.org/10.18632/oncotarget.20050 |
| [9] | Zak, K.M., Grudnik, P., Guzik, K., Zieba, B.J., Musielak, B., D？m-ling, A., Dubin, G. and Holak, T.A. (2016) Structural Basis for Small Molecule Targeting of the Programmed Death Ligand 1 (PD-L1). Oncotarget, 7, 30323-30335.
https://doi.org/10.18632/oncotarget.8730 |
| [10] | Guzik, K., Zak, K.M., Grudnik, P., Magiera, K., Musielak, B., T？rner, R., Skalniak, L., D？mling, A., Dubin, G. and Holak, T.A. (2017) Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimeri-zation of PD-L1. Journal of Medicinal Chemistry, 60, 5857-5867. https://doi.org/10.1021/acs.jmedchem.7b00293 |
| [11] | Qin, M., Cao, Q., Wu, X., Liu, C., Zheng, S., Xie, H., Tian, Y., Xie, J., Zhao, Y., Hou, Y., Zhang, X., Xu, B., Zhang, H. and Wang, X. (2020) Discovery of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction Inhibitors Bearing an Indoline Scaffold. European Journal of Me-dicinal Chemistry, 186, 111856-111868.
https://doi.org/10.1016/j.ejmech.2019.111856 |
| [12] | Cheng, B., Ren, Y., Niu, X., Wang, W., Wang, S., Tu, Y., Liu, S., Wang, J., Yang, D., Liao, G. and Chen, J. (2020) Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Pro-grammed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents. Journal of Medici-nal Chemistry, 63, 8338-8358.
https://doi.org/10.1021/acs.jmedchem.0c00574 |
